ateria health company logo

Ateria Health Ltd

Improving gut health. Backed by real science.

Business Highlights

  • JUVIA™ is a ground-breaking product for Irritable Bowel Syndrome (IBS) launching directly to consumers in the UK in August followed by roll-out to Australia
  • JUVIA™ contains our unique natural plant-based ingredient ERME™
  • ERME™ is a scientifically-validated and patent protected ingredient discovered by Ateria’s co-founders Prof. John Hunter and Dr Rosemary Waring following decades of research into gut health and the microbiome
  • IBS affects 10-15% of the global population. This is a large and rapidly growing market with limited effective treatments
  • Three global patents have been filed to cover the use of ERME™ in human health
  • No regulatory pre-approval is required to launch JUVIA™
  • Second product targeting athletic performance supported by positive clinical data
  • Expert Board and Management team with the inventors remaining on the Medical Advisory Board

Transaction Overview

Ateria Health is raising A$2.5M in a Series B Round at A$3.50 per share. All directors have participated.

Use of Funds A$ %
Launch Costs & Ongoing Marketing 1,600,000 64%
R&D (incl Clinical Trials) 500,000 20%
Working Capital & Capital Raise Fees 400,000 16%
TOTAL USE OF FUNDS 2,500,000 100%

 

Capital Structure

Issue Price A$3.50 per share
Market Cap Pre-Raise (fully diluted) ~A$16M
Indicative Capital Structure
Current shares outstanding 3,755,010
Shares issued in round 714,285
Total shares post round 4,469,295
Current options (Shareholder approved, not fully issued, at strike price no less than current round) 909,599
Fully diluted shares outstanding 5,378,894

 

Company Overview

Ateria Health Ltd (‘Ateria’) is a science backed health and wellness company, focused on the gut microbiome’s role in improving human health.

Ateria was founded in the UK in 2016 by the principals of Scientific Venture Partners, and Professor John Hunter and Dr Rosemary Waring, following decades of scientific research into the links between gut bacteria – the microbiome – and a range of conditions including irritable bowel syndrome, coeliac disease, colitis, diabetes and obesity.

Ateria has generated proof of concept data in human pilot studies demonstrating its product is safe and effective. Ateria has concluded two clinical studies in Perth, Western Australia and is launching its first product to treat IBS in August 2022.

Ateria’s first product, JUVIA™, is launching to the UK consumer market in August 2022.

 

How JUVIA™ works

Most IBS treatments don’t work because each of us has a unique gut microbiome.

JUVIA™ Digestive Balance Formula is a groundbreaking food supplement that works with your gut flora. Rather than introducing new bacteria to your system, JUVIA™ works with your gut flora by breaking down carbohydrates before they have a chance to cause problems in the gut.

JUVIA™ is backed by cutting-edge science and is both plant-based and sustainable and will be launched with a unique progress tracking app for customers.

Based in the UK, JUVIA™ is part of Ateria Health Ltd, a science-backed health and wellness company. Our products help digestion by adding enzymes to the diet.

What customers are saying…

“When I look back, I cannot believe the happy person I am now was the same miserable person I was 2 years ago. I would no longer class myself as having IBS and can confidently say that my bowels have completely returned to my normal. Thank you ERME! ” – EP, Female

“I have suffered with IBS for as long as I can remember. After taking ERME, I have been able to enjoy my favourite foods without the negative consequences” – TS, Male

“Since taking ERME I have found I can eat the foods that used to upset my bowels. I now have control over what I do and feel much more confident” – SB, Female

“ERME has given me the confidence to go about my day-to-day life with ease and be able to free my mind up for other things in life. I have more confidence in being able to eat a wider variety of things too” – MH, Male

Large & growing global market with unmet consumer needs

Ground breaking & natural plant-based product

Strong science & intellectual property

Capital light & IP heavy business model

Financials

Projected Sales

The company has projected sales of their first IBS product based on the following assumptions:

  • 12% population suffer from IBS (UK 8M, AUS 3M)
  • 3% penetration of IBS sufferers by year 3
  • Consumer price of £22 (~A$40) per bottle (30 doses)
Market Year 1 Year 2 Year 3
UK £M’s 3.6 11.6 21.7
AUS $M’s 2.5 7.8 14.8

Videos

Team

Rebecca Wilson

Director

Fred Edenius

Director

Harry Karelis

Director

Prof John Hunter

Clinical Advisor & Founder

Prof Rosemary Waring

Scientific Advisor & Founder

Dr Harry Fydenberg

Clinical Advisor

David Stern

Digital Marketing Consultant

Fiona Gatley

Food Industry Consultant

Dr Nigel Davies

Production Consultant

    Thank you for your enquiry.
    We will be in touch as soon as possible.